Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keros Therapeutics (KROS) has provided an announcement.
Keros Therapeutics, Inc. has announced significant executive transitions that will take effect from July 1, 2024. Jasbir Seehra will expand his leadership role as he becomes the Chair of the Board while retaining his CEO position, following his resignation as President. Christopher Rovaldi is set to become the new President, in addition to his ongoing role as COO. Moreover, Jean-Jacques Bienaimé has been appointed as the Lead Independent Director, with an added annual retainer for this position. These strategic moves aim to strengthen the company’s governance as it moves forward.
For detailed information about KROS stock, go to TipRanks’ Stock Analysis page.